ErascaERAS +0.16%22 3-Year ROIIC % is 31.74 as of Dec. 2025. GuruFocus rates ERAS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,324 Biotechnology companies, Erasca ranks better than 68.88% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Erasca's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 31.74%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Erasca's 3-Year ROIIC % or its related term are showing as below:
ERAS's 3-Year ROIIC % is ranked better than 68.88% of 1324
companies
in the Biotechnology industry
Industry Median: -4.63
vs ERAS: 31.74
Erasca (NAS:ERAS) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Erasca 3-Year ROIIC % Related Terms
Erasca 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Erasca's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERAS vs CELC, TNGX, DNTH: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Erasca's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Erasca's 3-Year ROIIC % falls into.
Erasca's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -131.405 (Dec. 2025) - -145.45 (Dec. 2022) )
/
( 127.054 (Dec. 2025) - 82.803 (Dec. 2022) )
=
14.045
/
44.251
=
31.74%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Erasca (ERAS) has a 3-Year ROIIC % of 31.74 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Erasca and its competitors. According to the industry distribution chart, Erasca ranks #412 out of 1324 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Erasca's 3-Year ROIIC % too high?
Erasca's current 3-Year ROIIC % is 31.74. Based on the distribution chart, Erasca ranks #412 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Erasca has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Erasca's 3-Year ROIIC % compare to CELC and TNGX?
According to the Biotechnology industry distribution chart, Erasca ranks #412 out of 1324 companies for 3-Year ROIIC %. This puts Erasca in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Erasca and its competitors. Erasca's current 3-Year ROIIC % is 31.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erasca stock overvalued right now?
Erasca (ERAS) has a current 3-Year ROIIC % of 31.74. The current 3-Year ROIIC % is 31.74. Erasca's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Erasca (ERAS), the current 3-Year ROIIC % is 31.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
22GF Score
Get the complete analysis for ERAS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERAS has been successfully added to your 
